慢性粒细胞白血病（cML）自应用马利兰域羟基据治疗以来已有30多年的历史，但并未改变CML的自然病程，且部分病例疗效不理想。美国Heste等人[1]总结西南肿瘤协作组18个单位用COAP方案治疗可使CML的中位存活期由马利兰治疗的36个月延长至45个月（女性）及58个月（男性），为此， Chronic myelogenous leukemia (cML) has been used for more than 30 years since the application of the Maillardian hydroxy group, but it has not changed the natural course of CML, and the efficacy of some cases is not satisfactory. Heste et al. [1] concluded that the treatment of 18 units of the Southwest Oncology Group with the COAP regimen could increase the median survival of CML from 36 months for the treatment of Marlyland to 45 months (for women) and 58 months (for men). to this end,